XML 81 R59.htm IDEA: XBRL DOCUMENT v3.20.4

Commitments and Contingencies (Details) - Zealand Pharma $ in Millions	12 Months Ended
	Dec. 31, 2020 USD ($)
Loss Contingencies [Line Items]
Amount of damages sought	$ 1.0
Loss contingency accrual	0.0
Successfully develop and commercialize Rusfertide Component with out partner
Loss Contingencies [Line Items]
Potential development and regulatory milestone payments on contractual obligation	28.0
Potential sales milestone payments on contractual obligation	$ 100.0

X

- Definition

Amount of potential development and regulatory milestone payments on contractual obligation

+ References

No definition available.

+ Details

Name:	ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount if potential sales milestone payments on contractual obligation.

+ References

No definition available.

+ Details

Name:	ptgx_PotentialSalesMilestonePaymentsOnContractualObligation
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of loss contingency liability.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349

+ Details

Name:	us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The value (monetary amount) of the award the plaintiff seeks in the legal matter.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349

+ Details

Name:	us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=ptgx_ZealandPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: